No Data
No Data
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Express News | Compugen To Receive $5M Milestone Payment From AstraZeneca Following Dosing Of First Patient In Second Phase 3 Trial Of Rilvegostomig
Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Compugen, Lowers Price Target to $4
Compugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 118.58% Truist Securities $5 → $4 Maintains Buy 03/08/2024 173.22% Truist Securities $4 → $5 Ma
No Data